1.Clinical presentation and prognosis in children over 10-year-old with primary nephrotic syndrome.
Juan TU ; Chao Ying CHEN ; Hong Xian YANG ; Yue JIA ; Hai Yun GENG ; Hua Rong LI
Chinese Journal of Pediatrics 2023;61(8):708-713
Objective: To summary the clinical presentation and prognosis of primary nephrotic syndrome (PNS) in teenagers. Methods: The clinical data, renal pathological types and prognosis of 118 children over 10-year-old with PNS treated in the Department of Nephrology of the Children's Hospital Affiliated to Capital Institute of Pediatrics from January 2010 to December 2020 were retrospectively analyzed, with 408 children ≤10-year-old as control group synchronously. Chi-square test was used to compare the difference of clinical types, pathologic types, response to steroids and tubulointerstitial changes between the groups. The teenagers with steroid resistant nephrotic syndrome (SRNS) were divided into initial non-responder group and late non-responder group. Kaplan-Meier method was used to compare the difference of persistent proteinuria, and Fisher's exact test for the histological types. Results: There were 118 children >10-year-old, including 74 males and 44 females, with the onset age of 12.1 (10.8, 13.4) years; and 408 children ≤10-year-old with the onset age of 4.5 (3.2, 6.8) years. The proportion of SRNS was significantly higher in patients >10-year-old than those ≤10-year-old (24.6% (29/118) vs. 15.9% (65/408), χ2=4.66, P=0.031). There was no statistical difference in the pathological types between >10-year-old and ≤10-year-old (P>0.05), with minimal change disease the most common type (56.0% (14/25) vs. 60.5% (26/43)). The percentage of cases with renal tubulointerstitial lesions was significantly higher in children >10-year-old compared to those ≤10-year-old (60.0% (15/25) vs. 23.3% (10/43), χ2=9.18, P=0.002). There were 29 cases presented with SRNS in PNS over 10-year-old, including 19 initial non-responders and 10 late non-responders. Analyzed by Kaplan-Meier curve, it was shown that the percentage of persistent proteinuria after 6 months of immunosuppressive treatments was significantly higher in initial non-responders than those of the late non-responders ((22±10)% vs. 0, χ2=14.68, P<0.001); the percentage of minimal change disease was significantly higher in patients of late non-responders than those of the initial non-responders (5/6 vs. 3/13, P=0.041). Of the 63 >10-year-old with steroid-sensitive nephrotic syndrome followed up more than one year, 38 cases (60.3%) had relapse, and 14 cases (22.2%) were frequent relapse nephrotic syndrome and steroid dependent nephrotic syndrome. Among the 45 patients followed up over 18-year-old, 22 cases (48.9%) had recurrent proteinuria continued to adulthood, 3 cases of SRNS progressed to kidney insufficiency, and one of them developed into end stage kidney disease and was administrated with hemodialysis. Conclusions: Cases over 10-year-old with PNS tend to present with SRNS and renal tubulointerstitial lesions. They have a favorable prognosis, but are liable to relapse in adulthood.
Male
;
Female
;
Adolescent
;
Child
;
Humans
;
Nephrotic Syndrome/pathology*
;
Retrospective Studies
;
Nephrosis, Lipoid/drug therapy*
;
Prognosis
;
Proteinuria/etiology*
;
Recurrence
2.Rifampicin-Induced Minimal Change Disease Is Improved after Cessation of Rifampicin without Steroid Therapy.
Dong Hyuk PARK ; Sul A LEE ; Hyeon Joo JEONG ; Tae Hyun YOO ; Shin Wook KANG ; Hyung Jung OH
Yonsei Medical Journal 2015;56(2):582-585
There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved complete remission after cessation of rifampicin without undergoing steroid therapy.
Aged
;
Antibiotics, Antitubercular/*adverse effects/therapeutic use
;
Edema/etiology
;
Female
;
Humans
;
Kidney Function Tests
;
Kidney Glomerulus/pathology
;
Nausea/etiology
;
Nephrosis, Lipoid/*chemically induced/pathology
;
Proteinuria
;
Remission Induction
;
Rifampin/*adverse effects/therapeutic use
;
Treatment Outcome
;
Tuberculosis, Pleural/*drug therapy
3.A Case of Minimal Change Disease Treated Successfully with Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus.
Young Hoon HONG ; Dae Young YUN ; Yong Wook JUNG ; Myung Jin OH ; Hyun Je KIM ; Choong Ki LEE
The Korean Journal of Internal Medicine 2011;26(4):470-473
The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours.
Antirheumatic Agents/therapeutic use
;
Female
;
Glucocorticoids/therapeutic use
;
Humans
;
Hydroxychloroquine/therapeutic use
;
Immunosuppressive Agents/*therapeutic use
;
Lupus Erythematosus, Systemic/complications/*pathology
;
Mycophenolic Acid/*analogs & derivatives/therapeutic use
;
Nephrosis, Lipoid/*drug therapy/etiology/pathology
;
Prednisone/therapeutic use
;
Young Adult